Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torsten Haferlach

Showing results (431-440 of 598) with videos related to

Pageof 60
Sort By:
Leukemia|August 6, 2020
Complex landscape of alternative splicing in myeloid neoplasmsCourtney E Hershberger, Devlin C Moyer, Vera Adema, et al.
Blood Advances|November 27, 2019
The ParaHox gene Cdx4 induces acute erythroid leukemia in miceSilvia Thoene, Tamoghna Mandal, Naidu M Vegi, et al.
Genome Medicine|May 20, 2024
Analysis of 3760 hematologic malignancies reveals rare transcriptomic aberrations of driver genesXueqi Cao, Sandra Huber, Ata Jadid Ahari, et al.
Oncotarget|May 1, 2018
Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profileVeronika Reidel, Johanna Kauschinger, Richard T Hauch, et al.
Nature Genetics|May 18, 2010
Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemiaMaria Kleppe, Idoya Lahortiga, Tiama El Chaar, et al.
Journal of Hematology & Oncology|August 3, 2023
Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasiaWaled Bahaj, Tariq Kewan, Carmelo Gurnari, et al.
Blood|March 6, 2010
Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1)Brunangelo Falini, Katja Macijewski, Tamara Weiss, et al.
American Journal of Hematology|July 12, 2019
Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapseLicia Iaccarino, Tiziana Ottone, Valentina Alfonso, et al.
Haematologica|November 26, 2008
Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosisSusanne Schnittger, Ulrike Bacher, Claudia Haferlach, et al.
Leukemia|April 24, 2025
Ruxolitinib mediated paradoxical JAK2 hyperphosphorylation is due to the protection of activation loop tyrosines from phosphatasesSivahari P Gorantla, Lorenz Oelschläger, Gerin Prince, et al.
Pageof 60

Showing results (431-440 of 598) with videos related to

Sort By:
Pageof 60
Leukemia|August 6, 2020
Complex landscape of alternative splicing in myeloid neoplasmsCourtney E Hershberger, Devlin C Moyer, Vera Adema, et al.
Blood Advances|November 27, 2019
The ParaHox gene Cdx4 induces acute erythroid leukemia in miceSilvia Thoene, Tamoghna Mandal, Naidu M Vegi, et al.
Genome Medicine|May 20, 2024
Analysis of 3760 hematologic malignancies reveals rare transcriptomic aberrations of driver genesXueqi Cao, Sandra Huber, Ata Jadid Ahari, et al.
Oncotarget|May 1, 2018
Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profileVeronika Reidel, Johanna Kauschinger, Richard T Hauch, et al.
Nature Genetics|May 18, 2010
Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemiaMaria Kleppe, Idoya Lahortiga, Tiama El Chaar, et al.
Journal of Hematology & Oncology|August 3, 2023
Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasiaWaled Bahaj, Tariq Kewan, Carmelo Gurnari, et al.
Blood|March 6, 2010
Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1)Brunangelo Falini, Katja Macijewski, Tamara Weiss, et al.
American Journal of Hematology|July 12, 2019
Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapseLicia Iaccarino, Tiziana Ottone, Valentina Alfonso, et al.
Haematologica|November 26, 2008
Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosisSusanne Schnittger, Ulrike Bacher, Claudia Haferlach, et al.
Leukemia|April 24, 2025
Ruxolitinib mediated paradoxical JAK2 hyperphosphorylation is due to the protection of activation loop tyrosines from phosphatasesSivahari P Gorantla, Lorenz Oelschläger, Gerin Prince, et al.
Pageof 60